How to Address the IP Issues Specifically Associated with Polymorphic Forms
Add bookmark
How to Address the IP Issues Specifically Associated with Polymorphic Forms
Add bookmarkIt is becoming increasingly important to have a successful application and litigation strategy to protect and maximise the revenue from existing patents. A substantial proportion of pharmaceutical products are crystalline forms which, due to the intricacies of obviousness and novelty, are notoriously difficult to patent and litigate. In this podcast Dr. Alpesh Pathak, Head - Patent Cell at Alembic Research Center, shares his insights with Andrea Charles from Pharma IQ, regarding the IP landscape for pharmaceutical crystalline and polymorphic forms. Pathak also discusses the unique challenges surrounding patenting pharmaceutical crystalline and polymorphic forms and how the industry is responding to these issues.
[inlinead]
Tags:
Alpesh Pathak
IP landscape
IP strategies
crystalline forms
patents
pharmaceutical crystalline forms
lifecycle extension
litigation
polymorphic forms
pharmaceutical patenting
patent wealth
effective patenting
Patent
